

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

Marinkovic-Radosevic, Jelena; Cigrovski Berković, Maja; Kruezi, Egon; Bilić-Ćurčić, Ines; Mrzljak, Anna

Source / Izvornik: **World Journal of Diabetes, 2021, 12, 932 - 938**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.4239/wjd.v12.i7.932>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:486113>

Rights / Prava: [Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-07-17**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

Jelena Marinkovic-Radosevic, Maja Cigrovski Berkovic, Egon Kruezi, Ines Bilic-Curcic, Anna Mrzljak

ORCID number: Jelena Marinkovic-Radosevic 0000-0002-0479-4253; Maja Cigrovski Berkovic 0000-0003-0750-9785; Egon Kruezi 0000-0002-4801-8037; Ines Bilic-Curcic 0000-0002-8861-5987; Anna Mrzljak 0000-0001-6270-2305.

Author contributions: Marinkovic-Radosevic J and Cigrovski Berkovic M made contributions to the conception and design of the study, drafted, and revised the manuscript critically; Kruezi E, Bilic-Curcic I, and Mrzljak A collected data, drafted and wrote the manuscript; All authors read and approved the final manuscript.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Jelena Marinkovic-Radosevic, Department of Endocrinology, Diabetes and Metabolism, Sisters of Charity Clinical Hospital Centre, Zagreb 10000, Croatia

Maja Cigrovski Berkovic, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Zagreb 10000, Croatia

Maja Cigrovski Berkovic, Department of Kinesiological Anthropology and Methodology, Faculty of Kinesiology, University of Zagreb, Zagreb 10000, Croatia

Egon Kruezi, Department of Gynecology and Obstetrics, Sisters of Charity Clinical Hospital Centre, Zagreb 10000, Croatia

Ines Bilic-Curcic, Department of Pharmacology, Faculty of Medicine, University of J. J. Strossmayer Osijek, Osijek 31000, Croatia

Ines Bilic-Curcic, Clinical Hospital Center Osijek, Osijek 31000, Croatia

Anna Mrzljak, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb 10000, Croatia

Corresponding author: Maja Cigrovski Berkovic, MD, Assistant Professor, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Ulica Gojka Šuška 6, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences. A plethora of symptoms and their severity differentiate on an individual level, giving the syndrome numerous phenotypes. Due to menstrual cycle abnormalities, women suffer from irregular menstrual bleeding, difficulty in conception, and infertility. Furthermore, the risk of pregnancy complications such as gestational diabetes mellitus, hypertensive disorders of pregnancy, and preterm birth are higher in women with PCOS than in the general population. Often, women with PCOS have comorbidities such as dyslipidemia, obesity, glucose intolerance or diabetes type 2, non-alcoholic fatty liver disease, and metabolic syndrome, which all influence the treatment plan. Historic insulin-sensitizing agents, although good for some of the metabolic derangements, do not offer long-term cardiovascular benefits; therefore, new treatment options are of

Manuscript source: Invited manuscript

Specialty type: Medicine, general and internal

Country/Territory of origin: Croatia

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Received: March 13, 2021

Peer-review started: March 13, 2021

First decision: March 30, 2021

Revised: March 30, 2021

Accepted: June 22, 2021

Article in press: June 22, 2021

Published online: July 15, 2021

P-Reviewer: Morozov S

S-Editor: Liu M

L-Editor: Filipodia

P-Editor: Wang LL



paramount importance. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, a new class of antidiabetic agents with beneficial cardiovascular, bodyweight, and antihyperglycemic effects, although not approved for the treatment of PCOS, might be an attractive therapeutic addition in the PCOS armamentarium. Namely, recent studies with SGLT-2 inhibitors showed promising improvements in anthropometric parameters and body composition in patients with PCOS. It is important to further explore the SGLT-2 inhibitors potential as an early therapeutic option because of the PCOS-related risk of metabolic, reproductive, and psychological consequences.

Key Words: Polycystic ovary syndrome; Sodium-glucose co-transporter-2 inhibitors; Metabolic risk; Cardiovascular risk; Metabolic syndrome; Insulin resistance; Obesity; Type 2 diabetes mellitus; Dyslipidemia

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a new class of antidiabetic agents with beneficial cardiovascular, bodyweight, and antihyperglycemic effects. Although not approved for the treatment of polycystic ovary syndrome (PCOS), they might be an attractive therapeutic addition for the related metabolic, reproductive, and psychological consequences. Recent studies with SGLT-2 inhibitors in PCOS patients showed promising improvements in anthropometric parameters and body composition. Thus, it is important to explore the SGLT-2 inhibitors potential as an early therapeutic option in PCOS due to its high cardiometabolic risk.

Citation: Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. *World J Diabetes* 2021; 12(7): 932-938

URL: <https://www.wjgnet.com/1948-9358/full/v12/i7/932.htm>

DOI: <https://dx.doi.org/10.4239/wjd.v12.i7.932>

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a complex condition defined by metabolic, fertility, and psychological consequences, with a prevalence of up to 20% among females of reproductive age[1]. It is diagnosed according to Rotterdam criteria (2 of the following): Oligo- or anovulation, clinical and/or biochemical hyperandrogenemia, or polycystic ovarian morphology on ultrasound[2]. Underlying pathologic processes create a broad spectrum of clinical and laboratory abnormalities. The underlying mechanisms are still inconclusive, however certain genetic traits[3-5], altered gonadotropin secretion[6,7], faulty ovarian follicle maturation[8], and insulin resistance (IR)[9] are considered the most important etiological factors. IR leads to hyperinsulinemia which precipitates hyperandrogenaemia by stimulating ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin (SHBG) production[10].

A plethora of symptoms and their severity differentiate on an individual level, giving the syndrome numerous phenotypes. Due to menstrual cycle abnormalities, women suffer from irregular menstrual bleeding, difficulty in conception, and infertility. Furthermore, the risk of pregnancy complications such as gestational diabetes mellitus, hypertensive disorders of pregnancy, and preterm birth are higher in women with PCOS than in the general population[11,12].

Although cardiometabolic risk factors are not part of the PCOS diagnostic criteria, they impact the treatment and prognosis[13]. Metabolic issues related to PCOS increase the risk for long-term consequences such as dyslipidemia, obesity, glucose intolerance[14], diabetes type 2[15-17], low-grade chronic inflammation[18], non-alcoholic fatty liver disease[19,20] and metabolic syndrome[21,22]. Consequently, all women with PCOS should be assessed for cardiovascular risk factors and global cardiovascular disease risk[2].

Treatment goals for PCOS include diminishing clinical hyperandrogenism, managing menstrual dysfunction, preventing endometrial hyperplasia and carcinoma, accomplishing ovulation in pursuit of pregnancy, and regulating metabolic issues in the long term. Lifestyle changes and weight loss are the cornerstones of treatment[23]. Oral contraceptives (OCs) are the first line of PCOS pharmacotherapy due to their effect on hyperandrogenism, menstrual irregularity, and endometrial carcinoma prevention[2,24]. In cases of prevalent hyperandrogenism despite OCs, antiandrogens can be added. When pursuing pregnancy, ovulation induction should be considered with clomiphene citrate, letrozole, and, rarely, gonadotropins[25]. If weight loss and ovulation induction are not successful, the next step is *in vitro* fertilization.

In the case of metabolic derangements, insulin-sensitizing agents, primarily metformin and thiazolidinediones, are widely used as an alternative or add-on to OCs [26,27]. Studies of newer glucose-lowering agents, such as glucagon-like peptide-1 receptor analogs (GLP-1RA) used for the treatment of obese women with PCOS, revealed a reduction of body weight, increase in menstrual frequency, and improvement of hyperandrogenemia and metabolic derangements even more effectively than metformin[28,29]. The down-side of the mentioned therapy might be a subcutaneous way of application.

PCOS AND CARDIOMETABOLIC RISK

One of the most important pathophysiological processes involved in PCOS development includes IR. The prevalence of IR in PCOS is high: it affects 75% of lean and 95% overweight women[30]. IR represents a link towards increased cardiometabolic risk leading to conditions such as hypertension, glucose intolerance or diabetes, dyslipidemia, and obesity[9,31].

Up to 70% of PCOS women demonstrate IR, glucose intolerance, and overt diabetes [32]. An American study on Women's Health Across the Nation showed a higher prevalence of impaired glucose tolerance (IGT) in PCOS (25%) compared to controls (9.2%)[33]. Moreover, a recent meta-analysis in women with PCOS demonstrated an increased prevalence of type 2 diabetes (T2DM) (odds ratio = 2.87, 95% CI: 1.44-5.72) [34]. Interestingly, 15%-36% of all T2DM diagnosed in women, irrespective of age, is found in association with PCOS. Women with PCOS often exhibit insulin secretory impairment, which accelerates the progression from IGT to T2DM 5 to 10-fold compared to the non-PCOS population, leading to prevalence rates of T2DM 5 to 7-fold higher than those reported in population-based studies of women aged 20-44 years[15,35].

In addition, dyslipidemia occurs in up to 70% of women with PCOS, most commonly characterized by high triglyceride, increased small dense LDL-C levels, and low HDL-C levels[36]. Obesity is also highly prevalent in PCOS; up to 60% of women with PCOS have body mass index (BMI) in the overweight or obesity range, which predisposes them to IR, gonadotropin secretion disturbances, hyperandrogenemia, and low SHBG secretion[37-39]. Consequently, metabolic syndrome is commonly found in women with PCOS (prevalence of 33%-47% in the United States, and 8%-25% in other countries)[36].

According to the recent guidelines, all women with PCOS should be screened for cardiovascular risk factors. Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society recommends categorizing PCOS related cardiovascular disease (CVD) risk as patients at risk (PCOS patients with obesity, cigarette smoking, hypertension, dyslipidemia, subclinical vascular disease, IGT, family history of premature CVD) or high risk (PCOS patients with metabolic syndrome, diabetes mellitus or overt vascular/renal disease)[36].

ROLE OF SGLT-2 INHIBITORS IN PCOS

Multiple metabolic disorders are well recognized among PCOS patients, so assessing the glycemic status is essential. If IGT is detected, lifestyle interventions together with insulin-sensitizing agents such as metformin and thiazolidinedione can be added to improve insulin sensitivity[31]. There are no dedicated metformin studies to confirm its effects on superior BMI reduction compared to placebo or decrease in central adiposity, a good marker for metabolic syndrome[26,27]. Incretins, primarily GLP-1RAs, have the potential to overcome metabolic derangements of PCOS and adding cardiovascular benefits. However, their use is limited by the need for subcutaneous

PCOS related cardiometabolic risk




Figure 1 Potential benefits of sodium-glucose co-transporter-2 inhibitors in treatment of different metabolic and cardiovascular features of polycystic ovary syndrome. NAFLD: Non-alcoholic fatty liver disease; PCOS: Polycystic ovary syndrome; SGLT-2i: Sodium-glucose co-transporter-2 inhibitors; T2DM: Type 2 diabetes.

application, while dipeptidyl peptidase-4 inhibitors, oral incretin therapy, lack the evidence of cardiovascular protection in recently published dedicated CVOTs[40]. Therefore, there is still a considerable demand for safe and effective therapeutic agents, offering solutions against PCOS's metabolic dysregulation.

Although SGLT-2 inhibitors are not approved for PCOS treatment, this class of antidiabetic drugs could be useful for PCOS patients due to beneficial glycaemic and cardiovascular effects, which are often an issue in women affected by PCOS[41] (Figure 1).

SGLT receptors are not found on ovaries, but their inhibition can indirectly improve metabolic status disrupted in certain PCOS patients. The role of SGLT-2 inhibitors in the treatment of PCOS is not yet well studied. Their mode of action can contribute to several pathophysiologic disorders in PCOS, including previously mentioned IR, hypertension, obesity, and dyslipidemia. By binding to SGLT-2 receptors in the proximal convoluted tubule of the kidney, gliflozins inhibit glucose and sodium reabsorption, causing a decrease in blood glucose levels, glucosuria, and natriuresis, which contributes to lowering blood pressure. Gliflozins promote glucose urine excretion by 60-80 g per day (approximately 240-320 kcal/d), promoting weight loss by approximately 1.7 kg. The action of SGLT-2 inhibitors does not depend on insulin secretion, beta-cell function, or IR[42,43].

SGLT-2 inhibitors achieve a further reduction in blood glucose levels by increasing insulin sensitivity, increasing glucose uptake in the muscle, decreasing gluconeogenesis in the liver, and improving the first phase of insulin release from the pancreatic beta-cells.

All mentioned processes improve metabolic profiles in diabetic patients, including lipid levels and serum uric acid levels, which could also be beneficial for PCOS patients[44]. Research also suggests the role of SGLT-2 inhibitors in preserving beta-cell function by indirectly reducing insulin secretion and promoting glucagon secretion. The latter plays a role in enhancing lipolysis and reducing the liver and visceral adipose tissue[45].

Besides the expected effect of SGLT-2 inhibitors on glycaemic control, they are also shown to be cardioprotective[46], which is an important benefit regarding an increased risk of cardiovascular disease in PCOS.

So far, only one randomized controlled trial compared the effects of empagliflozin (25 mg) *vs* metformin (1500 mg) on anthropometric and body composition, hormonal and metabolic parameters in 39 women with PCOS. Group treated with empagliflozin showed beneficial effects on weight, BMI, waist circumference and hip circumference, and total body fat in overweight and obese women with PCOS compared to metformin, but no differences were seen in hormonal and metabolic parameters, including IR and androgen levels[47]. The study comparing the effects of another SGLT-2 inhibitor, canagliflozin *vs* metformin in PCOS, is still underway (Clinical Trial Gov Identifier: NCT04700839).

CONCLUSION

Until more research confirms the positive metabolic effect of SGLT-2 inhibitors in PCOS patients, the mainstream treatment option will be lifestyle intervention, metformin, and oral contraceptive pills[24]. However, this treatment strategy does not successfully address long-term cardiometabolic consequences of PCOS[48], so SGLT-2 inhibitors, due to their mode of action, emerge as a potential new treatment option for PCOS.

ACKNOWLEDGEMENTS

The authors thank Antonije and Hrvojka Dolić for graphic design support.

REFERENCES

- 1 **Bozdag G**, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod* 2016; **31**: 2841-2855 [PMID: 27664216 DOI: 10.1093/humrep/dew218]
- 2 **Teede HJ**, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertil Steril* 2018; **110**: 364-379 [PMID: 30033227 DOI: 10.1016/j.fertnstert.2018.05.004]
- 3 **Vink JM**, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. *J Clin Endocrinol Metab* 2006; **91**: 2100-2104 [PMID: 16219714 DOI: 10.1210/jc.2005-1494]
- 4 **Kahsar-Miller MD**, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. *Fertil Steril* 2001; **75**: 53-58 [PMID: 11163816 DOI: 10.1016/s0015-0282(00)01662-9]
- 5 **Legro RS**, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. *Proc Natl Acad Sci USA* 1998; **95**: 14956-14960 [PMID: 9843997 DOI: 10.1073/pnas.95.25.14956]
- 6 **Balen AH**. Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. *Hum Reprod* 1993; **8** Suppl 2: 123-128 [PMID: 8276945 DOI: 10.1093/humrep/8.suppl_2.123]
- 7 **Jakimiuk AJ**, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. *J Clin Endocrinol Metab* 2001; **86**: 1318-1323 [PMID: 11238527 DOI: 10.1210/jcem.86.3.7318]
- 8 **Fauser BC**, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. *Endocr Rev* 1997; **18**: 71-106 [PMID: 9034787 DOI: 10.1210/edrv.18.1.0290]
- 9 **Osibogun O**, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. *Trends Cardiovasc Med* 2020; **30**: 399-404 [PMID: 31519403 DOI: 10.1016/j.tcm.2019.08.010]
- 10 **Sanchez-Garrido MA**, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. *Mol Metab* 2020; **35**: 100937 [PMID: 32244180 DOI: 10.1016/j.molmet.2020.01.001]
- 11 **Qin JZ**, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Reprod Biol Endocrinol* 2013; **11**: 56 [PMID: 23800002 DOI: 10.1186/1477-7827-11-56]
- 12 **Sha T**, Wang X, Cheng W, Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. *Reprod Biomed Online* 2019; **39**: 281-293 [PMID: 31255606 DOI: 10.1016/j.rbmo.2019.03.203]
- 13 **Oliver-Williams C**, Vassard D, Pinborg A, Schmidt L. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. *Eur J Prev Cardiol* 2020; 2047487320939674 [PMID: 32741211 DOI: 10.1177/2047487320939674]
- 14 **Legro RS**, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. *J Clin Endocrinol Metab* 2005; **90**: 3236-3242 [PMID: 15797965 DOI: 10.1210/jc.2004-1843]
- 15 **Ehrmann DA**, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 1999; **22**: 141-146 [PMID: 10333916 DOI: 10.2337/diacare.22.1.141]
- 16 **Ehrmann DA**, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Trogliatzone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005; **90**: 66-71 [PMID: 15507516 DOI: 10.1210/jc.2004-0229]
- 17 **Lo JC**, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse

- cardiovascular risk profile of diagnosed polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006; **91**: 1357-1363 [PMID: 16434451 DOI: 10.1210/jc.2005-2430]
- 18 **Spritzer PM**, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. *Reproduction* 2015; **149**: R219-R227 [PMID: 25628442 DOI: 10.1530/REP-14-0435]
 - 19 **Setji TL**, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006; **91**: 1741-1747 [PMID: 16492691 DOI: 10.1210/jc.2005-2774]
 - 20 **Rocha ALL**, Faria LC, Guimarães TCM, Moreira GV, Cândido AL, Couto CA, Reis FM. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. *J Endocrinol Invest* 2017; **40**: 1279-1288 [PMID: 28612285 DOI: 10.1007/s40618-017-0708-9]
 - 21 **Ford ES**, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. *Diabetes Care* 2004; **27**: 2444-2449 [PMID: 15451914 DOI: 10.2337/diacare.27.10.2444]
 - 22 **Apridonidze T**, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005; **90**: 1929-1935 [PMID: 15623819 DOI: 10.1210/jc.2004-1045]
 - 23 **Crosignani PG**, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Hum Reprod* 2003; **18**: 1928-1932 [PMID: 12923151 DOI: 10.1093/humrep/deg367]
 - 24 **Legro RS**, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2013; **98**: 4565-4592 [PMID: 24151290 DOI: 10.1210/jc.2013-2350]
 - 25 **Legro RS**, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H; NICHD Reproductive Medicine Network. Letrozole vs clomiphene for infertility in the polycystic ovary syndrome. *N Engl J Med* 2014; **371**: 119-129 [PMID: 25006718 DOI: 10.1056/NEJMoa1313517]
 - 26 **Morley LC**, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Cochrane Database Syst Rev* 2017; **11**: CD003053 [PMID: 29183107 DOI: 10.1002/14651858.CD003053.pub6]
 - 27 **Moggetti P**, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J Clin Endocrinol Metab* 2000; **85**: 139-146 [PMID: 10634377 DOI: 10.1210/jcem.85.1.6293]
 - 28 **Lamos EM**, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. *Expert Rev Clin Pharmacol* 2017; **10**: 401-408 [PMID: 28276778 DOI: 10.1080/17512433.2017.1292125]
 - 29 **Han Y**, Li Y, He B. GLP-1 receptor agonists vs metformin in PCOS: a systematic review and meta-analysis. *Reprod Biomed Online* 2019; **39**: 332-342 [PMID: 31229399 DOI: 10.1016/j.rbmo.2019.04.017]
 - 30 **Stepo NK**, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp. *Hum Reprod* 2013; **28**: 777-784 [PMID: 23315061 DOI: 10.1093/humrep/des463]
 - 31 **Goodarzi MO**, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol* 2011; **7**: 219-231 [PMID: 21263450 DOI: 10.1038/nrendo.2010.217]
 - 32 **Geller DH**, Pacaud D, Gordon CM, Misra M; of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). *Int J Pediatr Endocrinol* 2011; **2011**: 9 [PMID: 21899727 DOI: 10.1186/1687-9856-2011-9]
 - 33 **Polotsky AJ**, Allshouse A, Crawford SL, Harlow SD, Khalil N, Santoro N, Legro RS. Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. *J Clin Endocrinol Metab* 2012; **97**: E868-E877 [PMID: 22466350 DOI: 10.1210/jc.2011-3357]
 - 34 **Kakoly NS**, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. *Hum Reprod Update* 2018; **24**: 455-467 [PMID: 29590375 DOI: 10.1093/humupd/dmy007]
 - 35 **Legro RS**, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999; **84**: 165-169 [PMID: 9920077 DOI: 10.1210/jcem.84.1.5393]
 - 36 **Wild RA**, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of

- cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab* 2010; **95**: 2038-2049 [PMID: 20375205 DOI: 10.1210/jc.2009-2724]
- 37 **Azziz R**, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004; **89**: 2745-2749 [PMID: 15181052 DOI: 10.1210/jc.2003-032046]
- 38 **Legro RS**. Obesity and PCOS: implications for diagnosis and treatment. *Semin Reprod Med* 2012; **30**: 496-506 [PMID: 23074008 DOI: 10.1055/s-0032-1328878]
- 39 **Bajuk Studen K**, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. *Endocr Connect* 2018; **7**: R238-R251 [PMID: 29844207 DOI: 10.1530/EC-18-0129]
- 40 **Jensterle Sever M**, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. *Eur J Endocrinol* 2014; **170**: 451-459 [PMID: 24362411 DOI: 10.1530/EJE-13-0797]
- 41 **Moran LJ**, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. *Trends Endocrinol Metab* 2015; **26**: 136-143 [PMID: 25591984 DOI: 10.1016/j.tem.2014.12.003]
- 42 **Satoh H**. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. *Diabetol Int* 2018; **9**: 212-214 [PMID: 30603370 DOI: 10.1007/s13340-018-0367-x]
- 43 **Abdalla MA**, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. *Ther Adv Endocrinol Metab* 2020; **11**: 2042018820938305 [PMID: 32670541 DOI: 10.1177/2042018820938305]
- 44 **Verma S**, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia* 2018; **61**: 2108-2117 [PMID: 30132036 DOI: 10.1007/s00125-018-4670-7]
- 45 **Hallow KM**, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. *Am J Physiol Renal Physiol* 2018; **315**: F1295-F1306 [PMID: 30019930 DOI: 10.1152/ajprenal.00202.2018]
- 46 **Heerspink HJ**, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation* 2016; **134**: 752-772 [PMID: 27470878 DOI: 10.1161/CIRCULATIONAHA.116.021887]
- 47 **Javed Z**, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. *Clin Endocrinol (Oxf)* 2019; **90**: 805-813 [PMID: 30866088 DOI: 10.1111/cen.13968]
- 48 **Al Khalifah RA**, Florez ID, Zoratti MJ, Dennis B, Thabane L, Bassilious E. Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents. *J Endocr Soc* 2021; **5**: bvaa155 [PMID: 33324861 DOI: 10.1210/jendso/bvaa155]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

